Merck chairman and CEO Kenneth C. Frazier took the stage at the Forbes Healthcare Summit Thursday in New York to discuss the changing landscape of cancer treatment with fellow heavy hitters Mark Alles, CEO of Celgene; Giovanni Caforio, CEO of Bristol-Myers Squibb; and Robert Nelson, cofounder of ARCH Venture Partners. Frazier shared his thoughts on everything from cost vs. value to how one drug breakthrough leads to others and made one thing crystal clear: The man has a way with words.
